Format

Send to

Choose Destination
Reprod Toxicol. 2019 Jan 11;84:108-113. doi: 10.1016/j.reprotox.2019.01.003. [Epub ahead of print]

Pregnancy outcomes following maternal venlafaxine use: A prospective observational comparative cohort study.

Author information

1
UK Teratology Information Service, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK; Institute of Cellular Medicine, Newcastle University, Newcastle, UK. Electronic address: jonathan.richardson@nuth.nhs.uk.
2
Institute of Cellular Medicine, Newcastle University, Newcastle, UK.
3
UK Teratology Information Service, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK.
4
UK Teratology Information Service, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK; Institute of Cellular Medicine, Newcastle University, Newcastle, UK.
5
UK Teratology Information Service, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK; Institute of Genetic Medicine, Newcastle University, Newcastle, UK; Northern Genetics Service, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK.

Abstract

BACKGROUND:

Venlafaxine is a serotonin noradrenaline reuptake inhibitor used to treat major depressive episodes and anxiety disorders. The primary aim of this study was to investigate spontaneous abortion risks following gestational exposure.

METHODS:

This prospective observational comparative cohort study utilised data collected by the UK Teratology Information Service (UKTIS) between 1995 and 2018. The study sample included 281 venlafaxine exposed pregnancies matched to antidepressant unexposed (n = 1405) and SSRI exposed (n = 843) comparator groups.

RESULTS:

After correction for variation in competing outcome rates and the stage of pregnancy at reporting, no statistically significant differences in the hazard of spontaneous abortion was observed following gestational venlafaxine use compared with either antidepressant unexposed (HR 1.28, 95% CI; 0.850-1.94) or SSRI exposed (HR 1.03, 95% CI; 0.681-1.57) pregnancies.

CONCLUSIONS:

No conclusive evidence is provided from this study that venlafaxine increases the risk of adverse pregnancy or fetal outcomes.

KEYWORDS:

Birth defects; Congenital anomaly; Depression; Fetal growth; Fetotoxic effects; Fetus; Low birth weight; Miscarriage; Pregnancy; Prematurity; Preterm delivery; Small for gestational age; Spontaneous abortion; Teratogen; Venlafaxine

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center